NASDAQ:XGN

Exagen (XGN) Stock Forecast, Price & News

$2.42

-0.03 (-1.22%)

(As of 09/29/2023 ET)

Compare

Today's Range: $2.42
▼
$2.54
50-Day Range: $2.24
▼
$2.77
52-Week Range: $2.04
▼
$4.20

Volume: 5,033 shs
Average Volume: 11,215 shs
Market Capitalization: $40.80 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.25

Exagen MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 158.3% Upside
$6.25 Price Target
Short Interest: Healthy
0.15% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.29
Upright™ Environmental Score
News Sentiment: 0.59
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.62) to ($1.39) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

167th out of 971 stocks

Medical Laboratories Industry

7th out of 25 stocks

3.5

Analyst's Opinion

Consensus Rating
Exagen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.25, Exagen has a forecasted upside of 158.3% from its current price of $2.42.
Amount of Analyst Coverage
Exagen has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.15% of the float of Exagen has been sold short.
Short Interest Ratio / Days to Cover
Exagen has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Exagen has recently increased by 27.84%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Exagen does not currently pay a dividend.
Dividend Growth
Exagen does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Exagen has received a 70.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" and "Immunology laboratory services for research" products. See details.
Environmental Sustainability
The Environmental Impact score for Exagen is -1.29.

2.0

News and Social Media Coverage

News Sentiment
Exagen has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Exagen this week, compared to 0 articles on an average week.
Search Interest
Only 2 people have searched for XGN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exagen insiders have not sold or bought any company stock.
Percentage Held by Insiders
36.80% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
40.85% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Exagen are expected to grow in the coming year, from ($1.62) to ($1.39) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Exagen is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Exagen is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Exagen has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Exagen (NASDAQ:XGN) Stock

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

XGN Price History

30 days | 90 days | 365 days | Advanced Chart

XGN Stock News Headlines

September 29, 2023 | americanbankingnews.com

Exagen Inc. (NASDAQ:XGN) Short Interest Up 27.8% in September

September 28, 2023 | finance.yahoo.com

Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting

October 1, 2023 | Oxford Club (Ad)

Better Than Oil Stocks

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

September 27, 2023 | americanbankingnews.com

Exagen (NASDAQ:XGN) Stock Rating Reaffirmed by Cantor Fitzgerald

September 12, 2023 | finance.yahoo.com

Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

August 9, 2023 | finance.yahoo.com

Exagen Inc. (NASDAQ:XGN) Q2 2023 Earnings Call Transcript

August 7, 2023 | msn.com

Exagen beats Q2 top and bottom line estimates; initiates Q3 outlook

August 7, 2023 | finance.yahoo.com

Exagen Inc. Reports Strong Second Quarter 2023 Results

October 1, 2023 | Oxford Club (Ad)

Better Than Oil Stocks

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

August 4, 2023 | benzinga.com

Exagen's Earnings Outlook

July 26, 2023 | finance.yahoo.com

Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference

July 25, 2023 | finance.yahoo.com

Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023

July 24, 2023 | finance.yahoo.com

Exagen Inc. Appoints Paul Kim to Board of Directors

July 24, 2023 | finance.yahoo.com

This Exagen Insider Increased Their Holding In The Last Year

June 13, 2023 | finance.yahoo.com

Exagen Inc.'s (NASDAQ:XGN) Low P/S No Reason For Excitement

May 30, 2023 | finance.yahoo.com

Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference

May 17, 2023 | finance.yahoo.com

Exagen (NASDAQ:XGN) shareholders are up 20% this past week, but still in the red over the last three years

May 16, 2023 | msn.com

Cantor Fitzgerald Reiterates Exagen (XGN) Overweight Recommendation

May 16, 2023 | markets.businessinsider.com

Cantor Fitzgerald Reaffirms Their Buy Rating on Exagen (XGN)

May 16, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Exagen (XGN)

May 15, 2023 | finance.yahoo.com

Exagen Inc. Reports First Quarter 2023 Results

May 1, 2023 | finance.yahoo.com

Exagen Announces Campaign for Lupus Awareness Month

April 24, 2023 | finance.yahoo.com

Exagen to Announce First Quarter 2023 Financial Results on May 15, 2023

March 24, 2023 | finance.yahoo.com

Exagen Inc. (NASDAQ:XGN) Q4 2022 Earnings Call Transcript

March 22, 2023 | finance.yahoo.com

Exagen Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

March 20, 2023 | finance.yahoo.com

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

March 20, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Exagen's earnings

See More Headlines

Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

XGN Company Calendar

Last Earnings: 8/07/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:XGN
CUSIP: N/A
CIK: 1274737
Web: www.exagen.com
Phone: 760-560-1501
Fax: N/A
Employees: 199
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.25
High Stock Price Forecast: $7.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +158.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-47,390,000.00
Net Margins: -66.41%
Pretax Margin: -66.94%
Return on Equity: -74.00%
Return on Assets: -37.20%

Debt

Debt-to-Equity Ratio: 0.60
Current Ratio: 5.96
Quick Ratio: 5.96

Sales & Book Value

Annual Sales: $45.56 million
Price / Sales: 0.90
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.61 per share
Price / Book: 0.93

Miscellaneous

Outstanding Shares: 16,860,000
Free Float: 10,655,000
Market Cap: $40.80 million
Optionable: Not Optionable
Beta: 1.17

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Tina S. Nova Ph.D. (Age 69)
Exec. Chairman of Board
Comp: $65k

Mr. John Aballi (Age 38)
CEO, Pres & Director
Comp: $558.84k

Mr. Kamal Adawi M.S. (Age 44)
MBA, CFO & Corp. Sec.
Comp: $483.28k

Mr. Mark Hazeltine (Age 49)
Chief Bus. Officer
Comp: $483.28k

Ryan Douglas
Investors Relations Officer

Mr. John Wegener (Age 54)
Sr. VP of Sales and Marketing

Dr. Andrew L. Concoff FACR
M.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board

Dr. Michael I. Nerenberg M.D. (Age 68)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XGN Stock - Frequently Asked Questions

Should I buy or sell Exagen stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XGN shares.
View XGN analyst ratings or view top-rated stocks.
What is Exagen's stock price forecast for 2023?: 3 equities research analysts have issued 12 month price targets for Exagen's stock. Their XGN share price forecasts range from $5.00 to $7.00. On average, they expect the company's stock price to reach $6.25 in the next year. This suggests a possible upside of 158.3% from the stock's current price.
View analysts price targets for XGN or view top-rated stocks among Wall Street analysts.
How have XGN shares performed in 2023?: Exagen's stock was trading at $2.40 at the start of the year. Since then, XGN stock has increased by 0.8% and is now trading at $2.42.
View the best growth stocks for 2023 here.
Are investors shorting Exagen?: Exagen saw a increase in short interest in September. As of September 15th, there was short interest totaling 12,400 shares, an increase of 27.8% from the August 31st total of 9,700 shares. Based on an average trading volume of 15,100 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.2% of the company's stock are sold short.
View Exagen's Short Interest.
When is Exagen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our XGN earnings forecast.
How were Exagen's earnings last quarter?: Exagen Inc. (NASDAQ:XGN) issued its earnings results on Monday, August, 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.20. The business had revenue of $14.14 million for the quarter, compared to the consensus estimate of $10.97 million. Exagen had a negative trailing twelve-month return on equity of 74.00% and a negative net margin of 66.41%.
What guidance has Exagen issued on next quarter's earnings?: Exagen updated its third quarter 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $10.00 million-$10.50 million, compared to the consensus revenue estimate of $11.76 million.

What is Ron Rocca's approval rating as Exagen's CEO?: 5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees.
When did Exagen IPO?: (XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO.
What is Exagen's stock symbol?: Exagen trades on the NASDAQ under the ticker symbol "XGN."
How do I buy shares of Exagen?: Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Exagen's stock price today?: One share of XGN stock can currently be purchased for approximately $2.42.
How much money does Exagen make?: Exagen (NASDAQ:XGN) has a market capitalization of $40.80 million and generates $45.56 million in revenue each year. The company earns $-47,390,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis.
How many employees does Exagen have?: The company employs 199 workers across the globe.
How can I contact Exagen?: Exagen's mailing address is 1261 Liberty Way Suite C, VISTA CA, 92081. The official website for the company is www.exagen.com. The company can be reached via phone at 760-560-1501 or via email at ir@exagen.com.

This page (NASDAQ:XGN) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial